Welcome to our dedicated page for LGV news (Ticker: LGV), a resource for investors and traders seeking the latest updates and insights on LGV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LGV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LGV's position in the market.
On December 14, 2022, Longview Acquisition Corp. II's stockholders approved amendments to its Charter and Investment Trust Management Agreement. The amendments extend the deadline for completing a business combination to September 23, 2023. Following the amendments, stockholders redeemed 60,932,798 Public Shares for around $612.98 million, leaving 8,067,202 shares outstanding. The company plans to redeem all remaining Public Shares due to an inability to finalize a business combination by the new deadline and will begin the liquidation process. The securities are expected to be delisted from NYSE.
HeartFlow Holding, Inc. and Longview Acquisition Corp. II have announced a definitive merger agreement, aiming to enhance precision heart care. The merger will create HeartFlow Group, Inc., anticipated to list under HFLO. The transaction is valued at approximately $2.4 billion and is expected to provide $400 million in growth capital. HeartFlow specializes in non-invasive cardiac testing, targeting a market worth $10 billion, with plans to expand it to over $50 billion. The merger is set to close in Q4 2021, pending stockholder approval.
Longview Acquisition Corp. II (NYSE: LGV.U) announced that starting May 10, 2021, holders of its initial public offering units (69 million units) can separately trade shares of Class A common stock (symbol: LGV) and redeemable warrants (symbol: LGV WS). Units not separated will continue to trade under the symbol LGV.U. The offering was underwritten by UBS and Cowen. The SEC approved a registration statement for these securities earlier on March 18, 2021. The company, focusing on healthcare and other sectors, aims to create value for shareholders through strategic partnerships.
FAQ
What is the market cap of LGV (LGV)?
